• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

吉瑞替尼再次给药治疗伴有中枢神经系统复发的FLT3突变复发/难治性急性髓系白血病患者的安全性和有效性：一例病例报告

The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report.

作者信息

Ji Yueru, Wan Zhuo, Yang Jian, Hao Miaowang, Liu Li, Qin Weiwei

机构信息

Department of Hematology, Second Affiliated Hospital of Air Force Military Medical University, Xi'an, Shaanxi, China.

出版信息

Front Oncol. 2024 Jul 2;14:1402970. doi: 10.3389/fonc.2024.1402970. eCollection 2024.

DOI:10.3389/fonc.2024.1402970
PMID:39015500
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11250475/
Abstract

FLT3-ITD is a type of poor prognostic factors in acute myeloid leukemia (AML) disease. Gilteritinib, the second-generation FLT3 tyrosine kinase inhibitor, improved the overall survival of patients with relapsed/refractory FLT3-mutated AML in the ADMIRAL phase III trial. However, few data are available on the efficacy and safety of gilteritinib-based therapy for FLT3-mutated AML with central nervous system (CNS) involvement. We performed gilteritinib to treat a patient with CNS relapsed AML after allogeneic hematopoietic stem cell transplantation. The positive antileukemic effect of gilteritinib may bring new hope for the treatment of FLT3-mutated AML with CNS relapse.

摘要

FLT3-ITD是急性髓系白血病（AML）疾病中一种预后不良的因素。第二代FLT3酪氨酸激酶抑制剂吉瑞替尼在ADMIRAL III期试验中改善了复发/难治性FLT3突变AML患者的总生存期。然而，关于吉瑞替尼治疗中枢神经系统（CNS）受累的FLT3突变AML的疗效和安全性的数据很少。我们对1例异基因造血干细胞移植后CNS复发的AML患者进行了吉瑞替尼治疗。吉瑞替尼的阳性抗白血病作用可能为治疗CNS复发的FLT3突变AML带来新希望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34cd/11250475/edf8e40c8a3f/fonc-14-1402970-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34cd/11250475/edf8e40c8a3f/fonc-14-1402970-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34cd/11250475/edf8e40c8a3f/fonc-14-1402970-g001.jpg

相似文献

1
The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report.吉瑞替尼再次给药治疗伴有中枢神经系统复发的FLT3突变复发/难治性急性髓系白血病患者的安全性和有效性：一例病例报告
Front Oncol. 2024 Jul 2;14:1402970. doi: 10.3389/fonc.2024.1402970. eCollection 2024.
2
Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.在 3 期 ADMIRAL 试验中，比较 gilteritinib 与挽救化疗用于 FLT3 突变的复发/难治性急性髓系白血病患者移植后的结局。
Transplant Cell Ther. 2023 Apr;29(4):265.e1-265.e10. doi: 10.1016/j.jtct.2022.12.006. Epub 2022 Dec 13.
3
Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.ADMIRAL 研究中 gilteritinib 治疗复发/难治性 AML 伴 FLT3 突变患者的分子特征。
Blood Adv. 2022 Apr 12;6(7):2144-2155. doi: 10.1182/bloodadvances.2021006489.
4
Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.吉瑞替尼：一种用于急性髓系白血病的新型FLT3抑制剂。
Biomark Res. 2019 Sep 11;7:19. doi: 10.1186/s40364-019-0170-2. eCollection 2019.
5
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat -Mutated AML Patients.吉瑞替尼：从初步成功到治疗难治性突变急性髓系白血病患者的历程
J Clin Med. 2023 May 24;12(11):3647. doi: 10.3390/jcm12113647.
6
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.吉特替尼治疗后 FLT3 突变清除和治疗反应对 FLT3 突变阳性复发/难治性急性髓系白血病患者总生存期的影响。
Cancer Med. 2021 Feb;10(3):797-805. doi: 10.1002/cam4.3652. Epub 2020 Dec 19.
7
Rapid and Efficient Response to Gilteritinib and Venetoclax-Based Therapy in Two AML Patients with FLT3-ITD Mutation Unresponsive to Venetoclax Plus Azacitidine.两名对维奈克拉加阿扎胞苷无反应的FLT3-ITD突变急性髓系白血病患者对基于吉瑞替尼和维奈克拉的治疗产生快速有效反应
Onco Targets Ther. 2022 Feb 18;15:159-164. doi: 10.2147/OTT.S336715. eCollection 2022.
8
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.吉特替尼，一种 FLT3/AXL 抑制剂，在 FLT3 突变型急性髓系白血病的小鼠模型中显示出抗白血病活性。
Invest New Drugs. 2017 Oct;35(5):556-565. doi: 10.1007/s10637-017-0470-z. Epub 2017 May 17.
9
Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation.吉特替尼桥接治疗异基因造血干细胞移植后复发的急性髓系白血病。
J Infect Chemother. 2021 Apr;27(4):639-641. doi: 10.1016/j.jiac.2020.11.003. Epub 2020 Nov 17.
10
[Pharmacological and clinical profile of gilteritinib (Xospata tablets 40 mg), a therapeutic agent for relapsed or refractory FLT3-mutated acute myeloid leukemia].吉瑞替尼（Xospata片剂，40毫克）的药理及临床概况，一种用于复发或难治性FLT3突变急性髓系白血病的治疗药物
Nihon Yakurigaku Zasshi. 2021;156(1):37-46. doi: 10.1254/fpj.20050.

本文引用的文献

1
Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012 to 2022.排除中枢神经系统受累的急性髓系白血病患者参加临床试验：对 2012 年至 2022 年美国国立卫生研究院临床试验注册中心的分析。
Acta Haematol. 2024;147(3):292-299. doi: 10.1159/000533819. Epub 2023 Sep 26.
2
Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement.多机构分析伴中枢神经系统累及的急性髓系白血病患者的结局。
Leuk Lymphoma. 2023 Dec;64(12):2002-2007. doi: 10.1080/10428194.2023.2248331. Epub 2023 Aug 17.
3
How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia.
内部串联重复（ITD）插入位点如何调控FLT3-ITD突变型急性髓系白血病的生物学特性及疾病发生
Cancers (Basel). 2023 May 30;15(11):2991. doi: 10.3390/cancers15112991.
4
Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.FLT3 抑制剂在急性髓系白血病患者中的临床疗效。
Int J Mol Sci. 2022 Oct 21;23(20):12708. doi: 10.3390/ijms232012708.
5
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.吉特替尼联合阿扎胞苷与阿扎胞苷治疗新诊断的不适合强化化疗的 FLT3 突变阳性 AML 的 3 期临床试验。
Blood. 2022 Oct 27;140(17):1845-1857. doi: 10.1182/blood.2021014586.
6
Venetoclax Plus Gilteritinib for -Mutated Relapsed/Refractory Acute Myeloid Leukemia.维奈克拉联合吉特替尼治疗 - 突变的复发/难治性急性髓系白血病。
J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18.
7
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.复发脑膜急性髓系白血病伴 FLT3-ITD 阳性患者对吉特替尼治疗有反应。
Chemotherapy. 2021;66(4):134-138. doi: 10.1159/000518356. Epub 2021 Aug 24.
8
Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation.异基因造血干细胞移植后伴 FLT3-ITD 突变的急性髓系白血病髓外孤立复发采用吉特替尼治疗获得成功。
Int J Hematol. 2020 Aug;112(2):243-248. doi: 10.1007/s12185-020-02855-4. Epub 2020 Mar 13.
9
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.吉瑞替尼对复发或难治性急性髓系白血病中FLT3的选择性抑制作用：一项多中心、首例人体、开放标签的1-2期研究。
Lancet Oncol. 2017 Aug;18(8):1061-1075. doi: 10.1016/S1470-2045(17)30416-3. Epub 2017 Jun 20.
10
FLT3 and its role in the pathogenesis of acute myeloid leukaemia.FLT3及其在急性髓系白血病发病机制中的作用。
Leuk Lymphoma. 2003 Jan;44(1):1-7. doi: 10.1080/1042819021000040233.